Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. a randomized cross-over study

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Boesby, Lene ^a   Elung Jensen, Thomas ^a   Klausen, Tobias Wirenfeldt ^a   Strandgaard, Svend ^a   Kamper, Anne Lise ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FUROSEMIDE; POTASSIUM; ALDOSTERONE ANTAGONIST; DRUG DERIVATIVE; SPIRONOLACTONE;

ADD ON THERAPY; ADULT; AGED; ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERKALEMIA; HYPOTENSION; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; PROTEINURIA;

ADULT; AGED; ALDOSTERONE ANTAGONISTS; CROSS-OVER STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROTEINURIA; SPIRONOLACTONE;

EID: 80455145142     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026904     Document Type: Article

References (33)

1. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, et al. (2004) Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65: 2309-2320.
2. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, et al. (2001) Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60: 1131-1140.
3. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, et al. (1995) Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123: 754-762.
4. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G, (1998) Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int 53: 1209-1216.
5. Ruggenenti P, Perna A, Remuzzi G, (2003) Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 63: 2254-2261.
6. Kamper AL, Strandgaard S, Leyssac PP, (1992) Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 5: 423-430.
7. Kanno Y, Takenaka T, Nakamura T, Suzuki H, (2006) Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol 1: 730-737.
8. Epstein M, (2001) Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 37: 677-688.
9. Hostetter TH, Rosenberg ME, Ibrahim HN, Juknevicius I, (2001) Aldosterone in progressive renal disease. Semin Nephrol 21: 573-579.
10. Nagase M, Fujita T, (2008) Aldosterone and glomerular podocyte injury. Clin Exp Nephrol 12: 233-242.
11. Bianchi S, Bigazzi R, Campese VM, (2006) Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 70: 2116-2123.
12. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ, (2006) Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 1: 256-262.
13. Sato A, Hayashi K, Saruta T, (2005) Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 18: 44-49.
14. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, et al. (2005) Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 68: 2829-2836.
15. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, et al. (2006) Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 70: 536-542.
16. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, et al. (2006) Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1: 940-951.
17. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, et al. (2003) Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41: 1021-1026.
18. Cravedi P, Brusegan V, Ruggenenti P, Campbell R, Remuzzi G, (2010) Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work? Pharmaceuticals 3: 1-9.
19. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD, (2009) Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 20: 2641-2650.
20. Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, et al. (2008) Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 31: 59-67.
21. Tylicki L, Rutkowski P, Renke M, Larczynski W, Aleksandrowicz E, et al. (2008) Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 52: 486-493.
22. Bianchi S, Bigazzi R, Campese VM, (2005) Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 46: 45-51.
23. Uhrenholt TR, Schjerning J, Hansen PB, Norregaard R, Jensen BL, et al. (2003) Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ Res 93: 1258-1266.
24. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, et al. (2006) Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47: 1084-1093.
25. Rudolph AE, Rocha R, McMahon EG, (2004) Aldosterone target organ protection by eplerenone. Mol Cell Endocrinol 217: 229-238.
26. Arima S, (2006) Rapid non-genomic vasoconstrictor actions of aldosterone in the renal microcirculation. J Steroid Biochem Mol Biol 102: 170-174.
27. Schmidt BM, (2008) Rapid non-genomic effects of aldosterone on the renal vasculature. Steroids 73: 961-965.
28. Michea L, Delpiano AM, Hitschfeld C, Lobos L, Lavandero S, et al. (2005) Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 146: 973-980.
29. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717.
30. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, et al. (2001) The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 15: 79-87.
31. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, (2008) Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 118: 1643-1650.
32. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, et al. (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543-551.
33. Struthers A, Krum H, Williams GH, (2008) A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 31: 153-158.